Progyny, Inc.
About Progyny, Inc.
Progyny Inc is a benefits management company specializing in fertility, family building, and women's health benefits solutions. Its clients include employers across various industries. The fertility benefits solution consists of treatment services (Smart Cycles), access to the Progyny network of high-quality fertility specialists that perform the Smart Cycle treatments, and active management of the selective network of high-quality provider clinics.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $1.3B
- Net income
- $58.5M
- Total assets
- $742.4M
- Market cap
- $2.0B
- Gross margin
- 23.6%
- Operating margin
- 6.6%
- Net margin
- 4.5%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $1.3B
- Cost of revenue
- $984.2M
- Gross profit
- $304.5M
- Operating expenses
- $219.2M
- Operating income
- $85.3M
- Income tax
- $36.9M
- Net income
- $58.5M
- EPS (basic)
- $0.68
- EPS (diluted)
- $0.65
Balance sheet
- Total assets
- $742.4M
- Current assets
- $551.8M
- Total liabilities
- $226.4M
- Current liabilities
- $202.4M
- Shareholders’ equity
- $516.0M
Cash flow
- Operating cash flow
- $210.2M
- Investing cash flow
- -$159.0M
- Financing cash flow
- -$99.4M
- Net cash flow
- -$48.1M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $2.0B
- P/E ratio
- 39.9
- EPS (diluted)
- $0.65
- Shares outstanding
- 78.2M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 25, 2019
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $58.5M in FY2025.
- Revenue grew 274% from FY2020 to FY2025.
- Gross margin of 23.6%, net margin 4.5%.
- Trading 9% below its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 39.9.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Progyny, Inc..
Write a review
News about Progyny, Inc.
News & sentiment via Polygon.io
